Magnolia Medical Technologies is an innovative medical device company that is dedicated to improving healthcare outcomes by reducing diagnostic errors and the misdiagnosis of bloodstream infections. With a mission to achieve better outcomes for patients while battling antibiotic resistance, the brand offers a range of products and services that address contamination in blood culture collection. At the forefront of their offerings is the Steripath solution, an evidence-based technology platform that has been developed and proven to prevent unnecessary patient harm caused by misdiagnosis of sepsis.

By reducing false-positive central line-associated bloodstream infections (CLABSIs), Steripath not only improves patient safety but also significantly lowers system-wide costs for hospitals. Magnolia Medical Technologies holds an extensive intellectual property portfolio, with over 100 issued method, apparatus, and design patents, and multiple patent applications pending. This positions them as leaders in addressing various sources of diagnostic error harmful to patients.

As a brand, Magnolia Medical Technologies is driven by purposeful innovation, partnerships, and perseverance, with a vision to create a world free of in-vitro diagnostic errors where rapid, accurate test results improve the lives of patients and providers alike